Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies  by Boeckh, Michael et al.
C
T
C
I
i
m
l
u
p
e
t
e
Biology of Blood and Marrow Transplantation 9:543-558 (2003)
 2003 American Society for Blood and Marrow Transplantation
1
d
Bytomegalovirus in Hematopoietic Stem Cell
ransplant Recipients: Current Status, Known
hallenges, and Future Strategies
Michael Boeckh,1 W. Garrett Nichols,1 Genovefa Papanicolaou,2 Robert Rubin,3 John R. Wingard,4
John Zaia5
1Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, Washington; 2Memorial
Sloan-Kettering Cancer Center, New York, New York; 3Harvard Medical School, Brigham and Women’s Hospital
and Harvard/Massachusetts Institute of Technology, Division of Health Sciences and Technology, Boston,
Massachusetts; 4University of Florida College of Medicine, Gainesville, Florida; 5City of Hope National Medical
Center and Beckman Research Institute, Duarte, California
Correspondence and reprint requests: Michael Boeckh, MD, Program in Infectious Diseases, Fred Hutchinson
Cancer Research Center, P.O. Box 19024, Seattle, WA 8109-1024 (e-mail: mboeckh@fhcrc.org).
Received July 17, 2003; accepted August 1, 2003
ABSTRACT
Cytomegalovirus (CMV) infection is a major cause of morbidity and mortality after hematopoietic stem cell
transplantation. Significant progress has been made in the prevention of CMV disease over the past decade, but
prevention of late CMV disease continues to be a challenge in selected high-risk populations. The pretrans-
plantation CMV serostatus of the donor and/or recipient remains an important risk factor for posttransplan-
tation outcome despite the use of antiviral prophylaxis and preemptive therapy; CMV-seropositive recipients
of T cell–depleted grafts in particular continue to have a survival disadvantage compared with seronegative
recipients with seronegative donors. The risk of developing antiviral drug resistance remains low in most
patients; however, in a setting of intense immunosuppression (eg, after transplantation from a haploidentical
donor), the incidence may be as high as 8%. Primary CMV infection via blood transfusion can be reduced by
the provision of seronegative or leukocyte-depleted blood products; however, a small risk of 1% to 2% of CMV
disease remains. Surveillance and preemptive therapy are effective in preventing the sequelae of transfusion-
related CMV infection. Indirect immunomodulatory effects of CMV are increasingly recognized in hemato-
poietic stem cell transplant recipients. Strategies currently being investigated include long-term suppression
of CMV with valganciclovir for the prevention of late CMV infection and disease, adoptive transfer of
CMV-specific T cells, and donor and recipient vaccination strategies.
© 2003 American Society for Blood and Marrow Transplantation
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Historically, untreated cytomegalovirus (CMV)
nfection and disease were associated with signiﬁcant
orbidity in the early period after transplantation and
ed to mortality in nearly 25% of seropositive patients
ndergoing allogeneic hematopoietic stem cell trans-
lantation (SCT) [1-3]. Despite the introduction of
ffective antiviral therapies during the last 2 decades,
he mortality from late CMV disease and the indirectB&MTerm outcomes [4,5]. Furthermore, as hematopoietic
CT has evolved, less toxic nonmyeloablative condi-
ioning regimens coupled with intensive postengraft-
ent immunosuppressive therapies have enabled the
se of less selective transplant matches and have en-
bled older patients to undergo transplantation, with
ncreasing risks for subsequent opportunistic and re-
ctivated infections requiring further intervention.
Although signiﬁcant progress has been made in
iagnostic and prevention strategies, hematopoieticResistance
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ffects of CMV remain deterrents to successful long- SCT recipients exist in a dynamic environment and
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require constant surveillance and reassessment of viral
challenge. In particular, those high-risk recipients
characterized by treatment with high-dose corticoste-
roids, mycophenolate mofetil, and T-cell depletion or
anti–T-cell strategies are most vulnerable to CMV
infection. Also, long-term outpatient management
poses a more practical concern in some areas. During
this review of our current knowledge of CMV, risk
factors, prevention and treatment strategies, the po-
tential threat of CMV drug resistance, and unresolved
issues in our current prophylactic and therapeutic ap-
proaches will be discussed.
EFFECT OF CMV IN HEMATOPOIETIC SCT
Regardless of currently available antiviral strate-
gies, hematopoietic SCT recipients remain at risk for
CMV infection not only during the early posttrans-
plantation period (100 days), but also later (100
days) in the posttransplantation course. Before the
introduction of ganciclovir, the vast majority of CMV
infections occurred in the time period between en-
graftment and day 100 after hematopoietic SCT, with
sporadic occurrences before engraftment [6] (Figure
1). However, whereas the prevalence of early CMV
disease has declined to 3% to 6% with intense antivi-
ral drug use, the risk of late CMV disease has in-
creased over the past few years, with up to 18% of
recipients developing disease even when no preven-
tion is administered [7-12].
Effect of CMV Serostatus in the Era of Preemptive
Therapy and Prophylaxis
The issue of CMV serostatus in the ganciclovir era
is complex and continues as an area of active study
[13-21] (Table 1). Despite almost complete preven-
tion of CMV disease in most of these studies, positive
CMV serostatus of the recipient remains a poor prog-
nostic factor, especially in recipients of T cell–de-
pleted marrow or stem cells. An association of CMV
with graft-versus-host disease (GVHD) and nonviral
infections or sepsis has been suggested as a possible
mechanism [13,18]. A large study by Ljungman et al.
[16] demonstrated the importance of donor serostatus
among CMV-seropositive recipients of unrelated
grafts, possibly as a result of transferred CMV-speciﬁc
immunity from the donor to the recipient. In an anal-
ysis of a large cohort of T cell–replete SCT recipients,
both donor-positive/recipient-positive and donor-
positive/recipient-negative recipients had a higher risk
of mortality [18]. After controlling for neutropenia
and CMV disease, only donor-positive/recipient-neg-
ative recipients had a higher risk of mortality. The
authors attributed this outcome to indirect immuno-
modulatory effects of CMV because there was an
excess mortality due to bacterial and fungal infections
when compared with donor-negative/recipient-nega-
tive recipients [18]. Collectively, these studies of the
effect of CMV serostatus in the ganciclovir era suggest
that CMV infection before transplantation remains an
important factor leading to poor outcome after trans-
plantation, especially in recipients of T cell–depleted
transplants.
Effect of Source of Stem Cells and CD34 Selection
Recipients of transplants from unrelated or mis-
matched related donors in some analyses show an
increased risk of CMV disease, CMV-associated
death, and transplant-associated mortality [23].
Whereas altering the cellular components of the he-
matopoietic SCT through CD34 depletion is theoret-
ically advantageous in reducing contaminating tumor
cells, T cell–depleting the graft or CD34 selection in
both allogeneic [24,25] and autologous hematopoietic
SCT after myeloablative conditioning has shown a
notable increase in CMV disease and CMV-associated
deaths [26]. Investigation of the effect of the source of
stem cells on CMV infection provides conﬂicting re-
sults. Emergence of CMV infection and disease after
either unmodiﬁed peripheral blood SCT or bone mar-
row transplantation was evaluated in 2 studies. One
nonrandomized study (n  158) showed that the in-
cidences of CMV antigenemia (P  .01) and CMV
interstitial pneumonia (P  .04) were signiﬁcantly
reduced in the peripheral blood SCT recipients com-
pared with the bone marrow transplant recipients [26].
However, results from a randomized trial (n  172)
showed a higher incidence of CMV infection (P .04)
and a trend toward more CMV disease (P  .06) in
unmodiﬁed peripheral blood SCT recipients when
compared with bone marrow transplant recipients
[27].
Figure 1. Incidence of early (before day 100) versus late (after day
100) cytomegalovirus (CMV) disease by year of hematopoietic stem
cell transplantation in seropositive allogeneic recipients (n  1458).
Reprinted with permission [6].
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Effect of the Conditioning Regimen
Data are accumulating on the effect of the pre-
transplantation conditioning regimen on CMV inci-
dence and outcome. Myeloablative conditioning reg-
imens seek to destroy the existing cells, allowing for
replacement with the graft cells. With nonmyeloabla-
tive regimens, a mixed chimerism occurs, with coex-
istence of host and donor cells until the replacement
graft material prevails. Because myeloablative condi-
tioning regimens destroy host T cells (including the
cytotoxic T cells speciﬁc for CMV), the question has
been raised whether nonmyeloablative regimens
would result in less early CMV infection, a shorter
duration of neutropenia, reduced regimen-related tox-
icity, and a longer duration of host immunocompe-
tence when compared with myeloablative regimens.
To date, several nonmyeloablative and reduced-toxic-
ity conditioning regimens have been reported (Figure
2), although the corresponding level of immunosup-
pression varies. In a study of mostly HLA-matched
sibling transplant recipients with hematologic malig-
nancies undergoing either nonmyeloablative (total
body irradiation; 2 Gy) or conventional hematopoietic
SCT, CMV disease was signiﬁcantly delayed in the
nonmyeloablative group compared with the myeloab-
lative group (P  .02) [28]. However, the overall
incidence of CMV disease at 1 year was similar be-
tween the 2 conditioning regimens in recipients at
high risk (Figure 3). Notably, the incidence and onset
Table 1. Results of Selected Studies of Cytomegalovirus (CMV) Serostatus and Patient Outcomes
Study
No.
Patients T-Cell Depletion
Effect of CMV
Serostatus on Mortality Specific Outcomes
Broers [13] 115 Yes (n  109)
No (n  6)
Yes (recipient) 5-y survival significantly better for CMV-seronegative than
CMV-seropositive recipients, primarily because of
treatment-related mortality: 64% versus 40% (P  .01)
McGlave [21] 1423 Yes Yes (recipient) CMV-seronegative recipients had a lower risk of death or
relapse (hazard ratio, 0.80; P  .02)
Cornelissen [20] 127 Yes Yes (recipient) CMV-seronegative recipients had longer disease-free
survival (P  .05) and lower transplant-related
mortality (P  .08)
Craddock [15] 106 Yes Yes (recipient) 5-y survival significantly better for CMV-seronegative than
for CMV-seropositive recipients: 60% versus 42% (P 
.006)
Kroger [19] 125 Yes Yes (recipient) CMV-positive serostatus of recipient associated with
higher mortality (P  .014) and transplant-related
mortality (P  .02)
Ljungman [16] 7018 No Yes (donor)* For HLA-identical siblings, donor CMV serostatus had no
effect on outcomes in a univariate analysis
For unrelated donor transplants, recipients of CMV-
seropositive donor transplants had significantly
improved survival (P  .006) and treatment-related
mortality (P < .001) compared with recipients of CMV-
seronegative donor transplants
Castro-Malaspina [14] 510 Yes (n  389)
No (n  121)
Yes (recipient) CMV-negative recipient serostatus was associated with
significantly better overall survival (P  .002), reduced
treatment-related mortality (P  .004), and higher
cancerfree survival (P  .001)
Meijer [17] 253 Yes Yes (recipient) For recipients from matched, related donors, CMV
seropositivity of either donor or recipient was not
associated with survival or treatment-related mortality
For recipients from matched, unrelated donors, recipient
CMV seropositivity was associated with poorer survival
(P  .013) and treatment-related mortality (P  .0070)
Nichols [18] 1750 No Yes (recipient, donor) Highest mortality associated with CMV-seropositive
donor and CMV-seronegative recipient paining (P  .04)
or CMV-seropositive donor and CMV-seropositive
recipient paining (P  .03)
*This study examined the impact of donor CMV status among seropositive recipients. Effect of recipient serostatus was not evaluated.
Figure 2. Continuum of intensity from nonmyeloablative to my-
eloablative hematopoietic stem cell transplant-conditioning regi-
mens. ATG indicates antithymocyte globulin; TBI, total body ir-
radiation; MP, melphalan.
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of CMV antigenemia, as well as the time to antigen-
emia clearance, were also comparable [28]. There was
a trend toward more CMV infection and disease aris-
ing in unrelated donor transplant recipients [29].
However, a reduced-toxicity conditioning regimen of
alemtuzumab-1H (immunoglobulin G1 humanized
monoclonal anti-CD52) showed a high incidence of
CMV infection with very early reactivation of virus in
50% of patients at a median of 27 days after engraft-
ment [30]. The results of these studies suggest that the
choice of conditioning regimens affects the time of
CMV reactivation and disease, but the overall risks
have not been substantially reduced in the nonmyelo-
ablative SCT recipient.
Effect of Posttransplantation Immunosuppression
The immunosuppressive regimens that allow the re-
cipient to retain the graft and avoid the complications of
GVHD also play a role in CMV epidemiology. The net
state of immunosuppression experienced by the recipient
is modulated by factors such as pharmacologic therapies
(type, timing, duration, and sequence), immunogenetic
characteristics (HLA match), the presence or absence of
immunomodulating viruses, and metabolic abnormali-
ties [31]. Hematopoietic SCT recipients treated with
high-dose corticosteroids (1 mg/kg/d), mycophenolate
mofetil, T cell–depleted autografts or allografts, and
certain anti–T-cell strategies (eg, antithymocyte globu-
lin) are considered at high risk for CMV disease. In one
study, an increased risk of CMV disease or CMV-related
complications in allogeneic stem cell recipients was as-
sociated with mycophenolate mofetil treatment, which
seems to upregulate CMV [5]. In another study of allo-
geneic hematopoietic SCT recipients receiving intense
immunosuppression and preemptive therapy, based on 2
positive DNA polymerase chain reaction (PCR) assays,
the strategy failed because of the rapid rate of viral load
increase [32]. In this population, treatment at a lower
viral threshold is necessary and should not be delayed to
obtain a second positive diagnostic test.
What emerges from these studies is that highly
immunosuppressed recipients have delayed or reduced
immune reconstitution, which has a direct effect on
the viral replication dynamics in vivo [33]. Contrary to
widely held beliefs that CMV is a slowly replicating
virus (based on its time to clinical manifestations and
its slow growth in ﬁbroblast tissue cultures), the in
vivo increase of viral load progresses with a doubling
time of approximately 1 day in SCT recipients. The
likelihood of subsequent CMV disease development is
independently predicted by both the initial viral bur-
den and the rate of viral burden increase. Therefore,
measurement of these viral characteristics supports
identiﬁcation of recipients at immediate risk of CMV
disease [33,34]. Overall, recipients with a higher viral
burden are more prone to manifest CMV disease
during both the early and the late transplantation
periods [7,35]. The time frame for progression from
viral detection to overt disease with a rapidly increas-
ing viral load is compressed in highly immunosup-
pressed patients (eg, those taking 1 mg/kg/d of cor-
ticosteroids or those who are T-cell depleted) such
that any positive test should trigger immediate treat-
ment in these patients.
The same factors inﬂuence the viral load kinetics
in patients receiving antiviral treatment. Nichols et al.
[36] showed that viral load may increase in highly
immunosuppressed individuals receiving ganciclovir.
These viral load increases were seen in patients re-
ceiving high doses of corticosteroids.
LATE CMV DISEASE IN THE ERA OF PREEMPTIVE
THERAPY
Although preemptive ganciclovir therapy admin-
istered in response to pp65 antigenemia [8] or PCR
detection of CMV DNA [9] has dramatically reduced
early CMV disease after allogeneic hematopoietic
SCT, with concurrent improved survival in certain
high-risk recipients [9,37], the resulting increase in
the occurrence of late CMV disease has emerged as a
threat to long-term survival. A recent prospective
study explored the incidence and risk factors for late
CMV infection in seropositive allogeneic hematopoi-
etic SCT recipients receiving ganciclovir prophylaxis
either at engraftment or preemptively in response to
pp65 antigenemia, where routine antiviral drug use
terminated after 3 months (Figure 4) [7]. Of the 146
patients followed up, 17.8% developed late CMV dis-
ease at a median of 169 days after engraftment. CMV
disease was associated not only with a mortality rate of
46%, but also with recurrence in 38% of survivors [7].
Risk factors for late mortality and CMV disease are
Figure 3. Incidence of cytomegalovirus disease in high-risk hema-
topoietic stem cell transplant recipients after nonmyeloablative and
myeloablative conditioning regimens. Incidence at day 100, P .08;
incidence at day 365, P  87; day of onset, P  .02. Reprinted with
permission [28].
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shown in Table 2. Other studies have conﬁrmed that
chronic GVHD (P  .0017) and prior use of antiviral
therapy for longer than 4 weeks (P  .0073) are risk
factors for late CMV disease [10]. The authors of both
studies recommended continued monitoring for CMV
with rapid, sensitive techniques and prompt applica-
tion of preemptive therapy, especially for high-risk
recipients, in the late period after hematopoietic SCT.
Practically, the effectiveness of the preemptive
strategy depends on compliance with testing. Al-
though no randomized trials have been performed,
cohort studies suggest that viral monitoring should
occur weekly [28,38]. Thus, the logistics of frequent
testing must be arranged with the patient (especially in
the rural community setting). Although this has not
been well studied, the frequency of monitoring may be
reduced in patients receiving low doses of immuno-
suppression (ie, tapering doses of corticosteroids at
0.5 mg/kg/d) and in those without evidence of viral
reactivation for 4 weeks [7] (Boeckh and Nichols,
2003, unpublished data).
CLINICAL MANIFESTATIONS OF CMV DISEASE
The direct clinical manifestations of CMV disease
vary slightly for early compared with late disease. The
most common manifestations are pneumonia and gas-
trointestinal disease, which can occur from the esoph-
agus to the colon [39]. After day 100, manifestations
Figure 4. Cumulative incidence of late CMV disease in patients with the presence and absence of risk factors present at 3 months. Right,
graft-versus-host disease (GVHD; grade 2-4 or clinical chronic). Left: Any pp65 antigenemia (AG) before day 95 and CD4 count 50 cells
per cubic millimeter. Reprinted with permission [7].
Table 2. Risk Factors Associated with Late CMV Disease and Mortality in High-Risk Allogeneic Hematopoietic Stem Cell Transplant Recipients*
Variable
Relative Risk
(95% Confidence Interval)
P
Value
Risk factors present by month 3 after transplantation associated with mortality†
Absolute lymphocytopenia after day 40 (<100 cells/mm3) 1.8 (1.1-3.0) <.05
CD4 count (<50 cells/mm3) 1.9 (1.1-3.1) <.05
CD8 count (<50 cells/mm3) 2.5 (1.5-4.2) <.01
CMV pp65 antigenemia (any level positive) 1.8 (1.0-3.1) <.01
Surveillance risk factors present after day 95 after transplantation associated with late CMV disease‡
Lymphocytopenia (<300 cells/mm3) 9.4 (3.8-23.5) <.01
CMV DNA (plasma)
>1000 copies/mL 6.2 (1.0-39.2) <.05
>10 000 copies/mL 12.3 (1.8-85.1) <.01
CMV pp65 antigenemia (any level positive) 5.3 (1.5-19.1) <.01
Risk factors present after day 95 after transplantation associated with mortality‡
CMV disease 2.3 (1.2-4.2) <.01
Lymphocytopenia (<300 cells/mm3) 3.6 (1.9-6.7) <.01
*Adapted with permission [7].
†Univariate analysis.
‡Multivariate analysis.
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other than pneumonia and gastrointestinal disease are
sometimes observed, including CMV retinitis [40,41]
and central nervous system disease [13,42]. Standard-
ization of deﬁnitions for use in clinical studies of
CMV infection and disease in immunocompromised
patients has allowed more accurate assessments [43].
The indirect effects associated with CMV include
graft rejection, accelerated atherosclerosis, and bacte-
rial or fungal superinfections; these have been primar-
ily documented in solid organ transplantation [44-47].
Early studies with acyclovir prophylaxis for CMV in-
fection after bone marrow transplantation provided
preliminary indications of indirect CMV effects [48].
More recently, the indirect effects of primary CMV
infection were implicated in the higher incidence of
bacterial and fungal infection in a large cohort of
seronegative recipients of hematopoietic SCTs from
seropositive donors [18]. Efforts to elucidate and ame-
liorate these indirect effects have stimulated an im-
pressive body of research from clinical trials, as well as
basic research. Inclusion of indirect effects as valuable
end points (especially in clinical trials of drug thera-
pies) should help assess these effects [31,43].
CMV INFECTION DIAGNOSIS AND SURVEILLANCE
CMV disseminates through the blood during ac-
tive infection, and the presence of viremia is recog-
nized as the major virologic risk factor for progression
to clinical disease. Older techniques, such as culture-
based assays, failed to provide the rapid, sensitive, and
efﬁcient detection and quantitation required for pre-
diction of outcomes or initiation (or changes) of anti-
viral treatments [3]. In the era of preemptive antiviral
treatment strategies, the most universally applicable
clinical assays are CMV DNA detection methods and
the pp65 antigenemia assay. Recently, the pp67 mes-
senger RNA (mRNA) assay has been shown to be an
alternative to these methods [49]. In general, use of
PCR technology with either in-house or commercially
available assays to detect CMV DNA has proven an
excellent guide to trigger preemptive therapy. How-
ever, the individual assays vary in sensitivity, speciﬁc-
ity, and predictive value. Although plasma was long
considered a poor source for PCR-driven assays, im-
provement of these assays through sophisticated tech-
nology provides sensitivity similar to that of cell-based
sources [50,51]. Another practical issue concerns assay
variability. All quantitative measurements have a cer-
tain coefﬁcient of variation, so the general guideline
for a true increase or decrease in viral load is 0.5
log10—approximately a 3-fold difference. Although
the pp65 antigenemia assay, the pp67 mRNA assay,
and most DNA PCR assays perform well in clinical
practice [39] (Table 3), assay sensitivity and low vari-
ability of quantitation become especially critical for
highly immunosuppressed recipients, in whom the
viral load can increase rapidly [53]. For these recipi-
ents, monitoring by quantitative PCR with immediate
antiviral therapy at low levels without waiting for a
second positive test may affect CMV-related out-
comes [8,32,54,55].
CURRENT PREVENTION AND TREATMENT STRATEGIES
Prevention of Primary CMV Infection
For CMV-seronegative hematopoietic SCT recip-
ients, prevention focuses on use of seronegative do-
nors and blood products or use of leukocyte-reduced
blood products. However, the rate of CMV disease
with leukocyte-reduced blood products can be up to
2.4% [56]. In a follow-up study of 807 patients receiv-
ing leukocyte-reduced or seronegative blood prod-
ucts, ﬁltered red blood cell units (but not apheresis
platelet products) from CMV-positive donors were
associated with a signiﬁcant 32% increase in the odds
for transfusion-transmitted CMV (P  .006). These
results underscore that CMV-seronegative products
should remain a critical resource for high-risk pa-
tients [57]. Although posttransplant surveillance
and preemptive therapy are currently not uniformly
advocated [58,59], their use is highly effective in
eliminating complications of transfusion-related
CMV infection [57].
Prophylaxis Strategies
Immune Globulin and Antibody Therapy. The use of
CMV-speciﬁc intravenous immune globulin (IVIG)
for viral prophylaxis has been assessed in 2 separate
randomized, controlled trials of treatment of seroneg-
ative recipients of allogeneic bone marrow transplants
from seropositive donors, and these studies showed no
difference in disease incidence [60,61]. Other studies
of IVIG or CMV immunoglobulin have failed to show
either consistent positive results for CMV-related
complications or survival beneﬁts [62-65]. A trial with
a highly neutralizing monoclonal antibody (MSL-109)
speciﬁc to the CMV glycoprotein H also failed to
show a beneﬁt in seropositive hematopoietic SCT
recipients [66]. Overall, antibody treatments are not
currently recommended for CMV prophylaxis [58],
and uncertainty remains over the usefulness of IVIG
or hyperimmune globulin for the prevention of non-
CMV complications.
Acyclovir and Valacyclovir. The ﬁrst trial of antiviral
prophylaxis used acyclovir (500 mg/m2) intravenously
(IV) every 8 hours from 5 days before engraftment to
30 days after transplantation in seropositive allogeneic
bone marrow transplant recipients [67]. This prospec-
tive, nonrandomized study showed that high-dose
acyclovir therapy reduced the risk of CMV infection
and invasive disease, as well as mortality, in the ﬁrst
M. Boeckh et al.
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Table 3. Results of PCR-, pp67 mRNA–, and pp65 Antigenemia-Guided Preemptive Treatment Studies*
Study** Surveillance Control Group Treatment Regimen (Start/End) N
Incidence of CMV
Disease (day 100)
(%)
Randomized trials
Einsele [9] PCR CMV
DNA
Rapid culture-guided
ganciclovir
Ganciclovir and CMV Ig for 2
consecutive positive PCR
results; discontinuation after 2
wk or when PCR negative;
repeated treatment if PCR
positivity recurred
26† 7.7
Boeckh [8] pp65 AG Ganciclovir prophylaxis Ganciclovir for pp65 AG (>2
positive cells per 150 000 PBL;
discontinuation after 3 wk or 6
d after negative pp65 AG
assay; repeated treatment if
positive AG recurred
114†‡ 14.1§
Moretti [109] pp65 AG Preemptive foscarnet
or ganciclovir
Ganciclovir or foscarnet for 15 d
for pp65 AG (1 to 4 positive
cells per 200 000 PBL)
19 10.5
Humar [110] pp65 AG Day 35 BAL Positive pp65 AG: ganciclovir 5
mg/kg twice daily for at least 2
wk or until negative AG;
repeated treatment if
necessary
60 0
Positive BAL: ganciclovir 5 mg/
kg twice daily for 2 wk
followed by 8 wk of 5 mg/kg/d,
5 d/wk
Reusser [78] pp65 AG,
PCR CMV
DNA
Preemptive ganciclovir
or foscarnet for
positive AG or PCR
Ganciclovir: 14 d of 5 mg/kg
twice daily
110 (FSC) 3.3 (both groups
combined)¶
Foscarnet: 14 d of 60 mg/kg
twice daily
103 (GCV)
Continued maintenance therapy
if persistent positive screening
test at 2 wk
Gerna [49] pp67 mRNA pp65 AG Ganciclovir 5 mg/kg twice daily
until 2 negative tests
41 (pp67 mRNA)# 0 (both groups)
Nonrandomized trials
Ljungman [89] PCR CMV
DNA
Historical Ganciclovir for 2 consecutive
positive results DNA
39 (pp65 AG)#
58
6.0
Gerna [111] pp65 AG None Ganciclovir for pp65 AG (>2
positive cells per 200 000
PBL); discontinuation after 2
wk; maintenance for 7 to 14 d
in patients with GVHD;
repeated treatment if pp65
AG recurred
30# 6.6
Boeckh [112] pp65 AG Historical Ganciclovir for pp65 AG at any
level until day 100
102‡ 3.8
Einsele [10] PCR CMV
DNA
None Ganciclovir for 2 consecutive
positive PCR results for 14 d;
if still positive, foscarnet until
PCR negative
86 3.5
Reprinted with permission [39].
CMV indicates cytomegalovirus; PCR, polymerase chain reaction; Ig, immunoglobulin; AG, antigenemia; PBL, peripheral blood leukocyte;
BAL, bronchoaveolar lavage; FSC, foscarnet; GCV, ganciclovir; GVHD, graft-versus-host disease.
*Data refer to the incidence of CMV disease in seropositive recipients or seronegative recipients with seropositive donors.
†Incidence among engrafted patients.
‡Study includes only seropositive recipients.
§Disease before or after AG of 2 positive cells per slide, 8.8%; disease shortly after discontinuation of ganciclovir on the basis of a negative test, 5.3%.
Only disease after AG was reported; 1 patient was seronegative with a seronegative donor.
¶There was no difference in the incidence of CMV disease between the 2 groups. Incidence ﬁgures refer to the time after the start of study
drug rather than the entire ﬁrst 100 days.
#Pediatric patients only.
**Additional studies have been reported without data provided for day 100 [27,52].
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100 days after transplantation. With the apparent suc-
cess of acyclovir, a more extensive prospective, dou-
ble-blind trial showed a survival advantage for the IV
acyclovir/oral acyclovir group compared with the con-
trols (low-dose oral acyclovir/placebo group). There
was no difference in the incidence of CMV pneumo-
nia or other CMV diseases between the treatment
groups. The survival beneﬁt of 19% was maintained
through 1 year of follow-up. In addition, there seemed
to be fewer deaths related to bacterial and fungal
infections [48,68].
The development of a valine-ester prodrug of acy-
clovir, valacyclovir, allowed investigators to explore 2
issues limiting acyclovir use as CMV prophylaxis: (1)
poor oral bioavailability of the parent acyclovir and (2)
potential to expand dosage and the duration of treat-
ment with an improved oral formulation. One large
study randomized 727 seropositive (recipient-positive
or donor-positive) allogeneic bone marrow transplant
recipients to either oral valacyclovir (2000 mg) or oral
acyclovir (800 mg) 4 times per day for 18 weeks after
transplantation after prophylactic IV acyclovir therapy
(500 mg/m2 IV every 8 hours from 5 days before
engraftment to 28 days after transplantation) [69].
Treatment with valacyclovir signiﬁcantly reduced the
risk of CMV viremia compared with high-dose oral
acyclovir (28% versus 40%, respectively; P  .0001)
during the approximately 160 days of follow-up. Pre-
emptive treatment with ganciclovir guided by either
PCR or antigenemia detection of CMV resulted in a
low incidence of CMV disease in the valacyclovir
group (3.6%) and in the acyclovir group (5.6%). Sur-
vival did not differ between treatment groups. Toler-
ability was also similar for the 2 drugs [69]. In a subset
analysis, the effect of valacyclovir was seen mainly in
low-risk patients, whereas little effect was shown in
recipients of unrelated donor grafts. A small random-
ized trial of valacylovir versus intravenous ganciclovir
showed no statistically signiﬁcant difference in CMV
disease, neutropenia, and survival [70].
Ganciclovir. Results of early prophylaxis with gan-
ciclovir in seropositive allogeneic bone marrow trans-
plant recipients have been reported from 3 random-
ized, double-blind studies with slightly different
protocols [8,71,72]. Although all studies demonstrated
a signiﬁcant (P .001) reduction of CMV infection or
disease during the ﬁrst 100 days after engraftment, 2
studies also showed a signiﬁcant (P  .001 and P 
.002, respectively) and near-total prevention of CMV
disease during ganciclovir therapy [8,70]. No survival
advantage was demonstrated, and severe neutropenia
was observed in all studies and was potentially linked
to greater risks of fungal or bacterial infections
[8,71,72]. However, none of these studies had a sufﬁ-
ciently large sample size to evaluate survival as a study
end point. Thus, there was no detectable survival
beneﬁt with early prophylaxis in these 3 studies,
whereas analyses of large high-risk cohorts, such as
unrelated donor transplant recipients [37] and ran-
domized studies of preemptive therapy performed in
high-risk individuals, did show an effect of ganciclovir
on survival [9,73]. Studies listed in Table 1 indicate
that there are now important subsets of patients in
whom the use of ganciclovir prophylaxis or preemp-
tive therapy leads to the elimination of the survival
disadvantage associated with pretransplantation CMV
serostatus.
Foscarnet. Only small uncontrolled studies of fos-
carnet in hematopoietic SCT recipients have been
conducted for CMV prophylaxis. Renal toxicity has
limited widespread prophylactic use of this agent
[74,75].
Preemptive Strategies
Preemptive therapy in hematopoietic SCT recip-
ients refers to identiﬁcation of at-risk recipients by
using timely CMV detection with PCR techniques or
with quantitative pp65 antigenemia, followed by im-
mediate implementation of antiviral treatment on viral
detection (Figure 5). The premises of preemptive
therapy are that CMV viremia predicts disease devel-
opment and that viral load is a critical factor in patho-
genesis [3,35]. Therefore, this approach requires ac-
cess to reliable and rapid early diagnostic tests, strict
monitoring (at least weekly), and appropriate sample
selection [3]. Another risk-adapted strategy (some-
times called selected prophylaxis) uses immunologic and
Figure 5. Approximate time of CMV infection after allogeneic hematopoietic stem cell transplantation during the era of preemptive treatment
strategies with ganciclovir. GCV indicates ganciclovir; FSC, foscarnet; IP, interstitial pneumonia; BMT, bone marrow transplantation.
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virologic risk factors (eg, antithymocyte globulin ther-
apy, CMV antigenemia, or GVHD) to adjudicate ad-
ministration of a short course of ganciclovir. How-
ever, although this is reasonable in high-risk
situations, studies on this approach are sparse, and
general applicability remains untested [76,77].
Ganciclovir and Foscarnet. Currently, preemptive
therapy with IV ganciclovir has decreased the cumu-
lative incidence of CMV disease to rates ranging from
3.3% to 10.5% before day 100 after engraftment (Ta-
ble 3). Although most data are available for ganciclovir
regimens, both ganciclovir and foscarnet are used in
preemptive therapy. In a large randomized trial of 213
SCT recipients, preemptive therapy with foscarnet
was compared with that with ganciclovir; the inci-
dence of CMV disease was 5% in both groups [78].
Neutropenia was more frequently reported in the gan-
ciclovir arm, whereas impaired renal function and
electrolyte abnormalities were more frequent in the
foscarnet arm [78]. Despite the higher incidence of
neutropenia, the composite end point of CMV dis-
ease–free survival was not different between the
groups. A small study of reduced-dose ganciclovir and
foscarnet combinations did not show a reduction in
viral load or treatment-related toxicities [79].
Oral Ganciclovir and Valganciclovir. Pharmacoki-
netic evaluations of an oral ganciclovir formulation in
a phase I/II study showed that the presence of acute
GVHD of the gastrointestinal tract did not seem to
limit drug absorption, and, thus, the bioavailability of
the drug seemed appropriate for hematopoietic SCT
recipients. Gastrointestinal intolerance and neutrope-
nia in the early postengraftment period (before day
60) seemed to be impediments to the use of this
formulation [80]. Use of the oral ganciclovir formula-
tion later in the transplantation course after IV treat-
ment provided acceptable tolerability and efﬁcacy in
another study [81].
Valganciclovir is a valine-ester prodrug of ganci-
clovir that, in solid organ transplant recipients [82]
and human immunodeﬁciency virus–infected patients
[83], has improved bioavailability, resulting in an area
under the curve similar to that of IV ganciclovir. If the
early reports of drug usefulness are supported by cur-
rently ongoing clinical trials in hematopoietic SCT,
valganciclovir may become an alternative to IV gan-
ciclovir for some indications [84,85].
Cidofovir. Although randomized clinical trials have
not yet been performed, small, uncontrolled studies of
cidofovir in allogeneic hematopoietic SCT recipients
indicate that it may be effective as second-line therapy
in patients with CMV disease whose traditional anti-
viral treatments have failed [86] or in low-risk patients
after low-intensity conditioning regimens [87]. How-
ever, treatment-related toxicities (ie, renal and mar-
row impairments) and reports of cidofovir failures
prohibit its use as front-line preemptive therapy be-
fore comparative studies are conducted [86-88].
Initiation and Duration of Preemptive Therapy and
Viral Monitoring. The deﬁnitive threshold for trigger-
ing antiviral preemptive therapy remains undecided,
and centers continue to base their regimens primarily
on local experience and patient characteristics. In gen-
eral, initiation of therapy triggered by 2 consecutive
positive results with either DNA PCR-guided or any
positive pp65 antigenemia test result is effective in
allogeneic recipients receiving standard immunosup-
pression [9,54]. In cases of highly immunosuppressed
recipients, the faster increase in CMV levels warrants
therapy initiation at very low levels of virus detection
[32].
Various durations of antiviral treatment within
preemptive therapy have been explored. The original
studies continued any initiated ganciclovir therapy un-
til day 100 after engraftment (approximately 6 to 8
weeks in the average recipient). Studies from the mid
1990s of shorter ganciclovir courses based on negative
PCR assays at the end of therapy with a 3-week mean
[9] or a 2-week mean [89] were generally effective;
however, resumption of preemptive therapy was nec-
essary in approximately 30% of patients (Figure 5).
Most centers now continue antiviral treatment until
the designated viral marker is negative. If less sensitive
markers, such as the pp65 antigenemia assay or pp67
mRNA assay, are used, then preemptive therapy
should be continued until 2 negative assays are ob-
tained [69]. Induction dosing should continue until a
decline of viral load has been demonstrated [55].
If either the recipient or donor is seropositive,
weekly CMV surveillance is recommended until day
100 after engraftment. After day 100, weekly surveil-
lance should be continued in recipients at high risk for
disease on the basis of early patient characteristics [39]
(Table 4). Because 80% of CMV cases are docu-
mented before day 270 after engraftment [7], surveil-
lance should be performed during this period; the
duration and frequency of CMV monitoring in the
later transplantation periods have not been deter-
mined. Nonetheless, a surveillance strategy should
include considerations of the net immunosuppression
of the recipient (including corticosteroid treatments
for GVHD) and history of CMV reactivation. Thus,
selected patients with continued intense immunosup-
pression may beneﬁt from surveillance after day 270
after transplantation.
EFFECT OF DRUG-RESISTANT CMV STRAINS
Overall, ganciclovir resistance remains a rare oc-
currence in hematopoietic SCT recipients [36,42,90-
93] (Table 5). Most reports of ganciclovir resistance in
transplant recipients suggest that children with immu-
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nodeﬁciency syndromes or those who receive trans-
plants from haploidentical donors with T cell–de-
pleted allografts are at higher risk for development of
CMV strains resistant to ganciclovir (multidrug resis-
tance to foscarnet and cidofovir also occur) [93]. Al-
though children seem at higher risk in the early period
(days 44 to 95 after allogeneic engraftment with T
cell–depleted material) before recovery of immune
competence, ganciclovir resistance does not always
correlate with delayed immune recovery [94]. Ganci-
clovir resistance emerged in 2 adult haploidentical
hematopoietic SCT recipients after prolonged pre-
emptive therapy [42]. One case involved central ner-
vous system manifestations linked to mixed wild-type
and UL97 mutant viral populations in the cerebrospi-
nal ﬂuid. The second case resulted from a resistant
variant in the lung [42]. The incidence of ganciclovir
resistance in hematopoietic SCT continues to be
monitored through clinical response assessments and
identiﬁcation of resistance-associated mutations.
Resistance to ganciclovir results from mutations in
the viral DNA polymerase gene (UL54) and the viral
Table 4. Management of CMV Infection after Hematopoietic Stem Cell Transplantation: Recommendations [39]
Indication Strategy Comment
Prevention
Allogeneic transplantation
(myeloablative and
nonmyeloablative)
Antigenemia- or PCR-guided early ganciclovir
treatment: 5 mg/kg BID for minimum of 7
d or until viral load decreases (whichever
comes later), followed by 5 mg/kg/d until
day 100 or until serial negative PCR or
antigenemia*
Some cases of CMV disease may occur shortly
after discontinuation based on negative PCR
or antigenemia; thus, 2 negative tests are
required in high-risk settings
or
Seropositive recipient Ganciclovir prophylaxis at engraftment: 5 mg/
kg BID for 5 d followed by 5 mg/kg/d on 5-6
dy/wk until day 100
Recommended if neither PCR no antigenemia
testing is available
Seronegative recipient/
seropositive donor
Antigenemia- or PCR-guided early ganciclovir
treatment: 5 mg/kg BID for 7 d or until
viral load decreases, followed by 5 mg/kg/d
until day 100 (or until negative PCR or
antigenemia)*
Prophylaxis at engraftment not recommended
because of low incidence of
posttransplantation infection
and
Seronegative or leukocyte-reduced blood
products
Seronegative recipient/
seronegative donor
Seronegative or leukocyte-reduced blood
products
Breakthrough disease of up to 2.3%; virologic
monitoring and preemptive therapy effective
in reducing breakthrough rates but not
uniformly advocated
Autologous
transplantation,
seropositive recipient
Antigenemia- or PCR-guided early ganciclovir
treatment: 5 mg/kg ganciclovir BID for 7 d
or until viral load decreases, followed by 5
mg/kg/d for 14 to 21 d
Monitoring not uniformly advocated because of
very low risk in some settings (absence of
corticosteroids, TBI, CD34 selection); CD34-
depleted recipients represent a special
population that should be monitored
similarly to allogeneic recipients
Seronegative recipient Seronegative or leukocyte-reduced blood
products
Breakthrough disease of up to 2.3%; virologic
monitoring and preemptive therapy effective
in reducing breakthrough rates but not
uniformly advocated
Treatment of disease
CMV pneumonia Ganciclovir 5 mg/kg BID for 14 to 21 d (or
until declining viral load) followed by 5 mg/
kg/d for at least 3 to 4 wk plus IVIG 500
mg/kg or CMV Ig 150 mg/kg every other
day for 2 wk, then weekly
Extended maintenance throughout the period
of severe immunosuppression (ie, GVHD
treatment) may be considered
Gastrointestinal disease Ganciclovir 5 mg/kg BID for 14 to 21 d (or
until declining viral load) followed by 5 mg/
kg/d for at least 3 to 4 wk
If deep ulcerations are present, longer
maintenance may be required
Marrow failure Foscarnet 90 mg/kg BID for 14 d followed by
90 mg/kg/d for 2 wk plus G-CSF
Ganciclovir plus IVIG has also been used
Retinitis Ganciclovir 5 mg/kg BID for 14 to 21 d
followed by 5 mg/kg/d for at least 3 to 4 wk
Extended maintenance may be required;
ophthalmologic monitoring is required
TBI indicates total body irradiation; IVIG, intravenous immune globulin; Ig, immunoglobulin; G-CSE, granulocyte colony-stimulating factor;
BID, twice daily.
*Foscarnet has been shown to be equivalent with regard to efﬁcacy in 1 randomized trial [78].
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phosphotransferase gene (UL97), with mutations in
UL97 emerging ﬁrst (resulting in low-level resis-
tance), followed by the more severe resistance associ-
ated with UL54 mutations [91,95]. The development
of ganciclovir resistance is linked to the degree of
immunosuppression, the kinetics of viral replication,
the presence of mutant viral strains at the onset of
drug therapy, and the effectiveness and duration of
antiviral therapy. Situations in which prolonged sub-
clinical reactivation occurs in the presence of antiviral
drug predispose patients to development of drug re-
sistance. With quantitative virologic monitoring, in-
creases in viral load for 2 weeks on induction doses
of antivirals may be suggestive of viral resistance. Al-
though switching antiviral drug therapy to foscarnet
or cidofovir (which are not affected by the UL97
mutation) has shown beneﬁt, some cross-resistance
has been reported [93,95,96]. Use of the prodrug
valganciclovir in solid organ transplant recipients has
suggested that lower rates of resistance may occur
when compared with those seen with oral ganciclovir,
but data are not yet available for hematopoietic SCT
recipients [97].
FUTURE PHARMACOLOGIC AND IMMUNE THERAPIES
Clinical trials are under way with valganciclovir.
The drug is well absorbed, with proven efﬁcacy as
induction therapy in human immunodeﬁciency virus-
infected patients with new CMV retinitis, and pre-
emptive studies are ongoing [84]. However, absorp-
tion in SCT recipients with gastrointestinal GVHD
has not been studied. In hematopoietic SCT, random-
ized studies are ongoing to determine the role of
valganciclovir in preemptive therapy and for long-
term prophylaxis of late CMV infection and disease.
Initial uncontrolled reports show no breakthrough
disease in a small cohort of hematopoietic SCT recip-
ients receiving preemptive therapy [98]. Additional
drugs are in preclinical and clinical development [99,
100].
The profound and prolonged immunodeﬁciency
engendered by the processes necessary for hematopoi-
etic SCT provides the opportunity for CMV reacti-
vation. Current immunotherapy approaches involve 2
strategies: (1) early restoration of recipient CMV-
speciﬁc immunity with adoptive transfer of expanded
T-cell clones from donor material [101-103] and (2)
vaccination of stem cell donors with or without recip-
ient vaccination. For the adoptive transfer approach,
research interest has centered on restoration of CMV-
speciﬁc CD8 cytotoxic T cells, because initial studies
showed that these cells were capable of preventing the
development of CMV-associated disease in the early
postengraftment time frame [104]. More than a de-
cade ago, the potential of adoptive transfer of CMV-
speciﬁc CD8 T-cell clones propagated in vitro was
reported in allogeneic hematopoietic SCT recipients
[105]. More recently, adoptive transfer of cloned or
expanded CMV-speciﬁc CD8 T cells from the blood
of their CMV-seropositive donors was successfully
accomplished in allogeneic hematopoietic SCT recip-
ients, with resultant substantial increases in anti-CMV
cytotoxic activity and no treatment-related side effects
[101]. However, this study also highlighted the need
for concurrent transfer of CD4 helper T cells. An-
other recent study reported infusion of CMV-speciﬁc
T cells for the treatment of CMV infection not re-
sponding to antiviral chemotherapy [106].
A number of strategies to produce sufﬁcient quan-
tities of T cells appropriate for adoptive immunother-
apy have been explored; major technical issues include
maximizing comprehensive and efﬁcient antigen pre-
sentation and selection of the T-cell subsets most
likely to avoid the risk of GVHD. For expansion of
T-cell clones through presentation of exogenously
provided antigen, the choice of antigen-presenting
cells includes monocytes, dendritic cells, and B-lym-
phocyte cell lines. Techniques for presentation of en-
dogenously provided antigens have used a variety of
antigen-presenting cells, transduction versus transfec-
tion approaches, different vectors, and different anti-
gens. Approaches for selection of the most favorable
lymphocyte subset involve boosting cell numbers and
identifying and retrieving the cells [107]. Host factors
and immunosuppressive or treatment-related drugs
are likely to inﬂuence the success of immune recon-
stitution after hematopoietic SCT. In particular, use
of high-dose corticosteroids (1 mg/kg/d) has already
been identiﬁed as predicting poorer recovery of com-
petent T-cell immunity during the ﬁrst 3 months after
transplantation [108]. The major issues with clinical
application of adoptive immunotherapy include tech-
nical and time-dependent challenges, lack of appro-
priate donor material, further characterization of host
Table 5. Studies Documenting Ganciclovir Resistance in Hematopoietic
Stem Cell Transplant Recipients
Study Setting N
Incidence
(%)
CMV disease
Slavin [90] CMV interstitial pneumonia 12 8.3
CMV infection
Erice [91] CMV infection 15 6.7
Nichols [36] pp65 antigenemia (all) 119 0.8
Increasing pp65 antigenemia
(subset)
15 6.7
Boivin [92] pp65 antigenemia 34 0
All patients
Eckle [93] Unrelated
donor/haploidentical
79 3.8
Wolf [42] Allogeneic/haploidentical
(all)
138 1.4
Haploidentical (subset) 26 7.6
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and regimen effects, and the expense of this treatment
approach.
Extensive literature exists on CMV-directed vac-
cines using material derived from attenuated live virus,
recombinant live virus, viral DNA sequences, whole
CMV proteins, and peptides. However, these ap-
proaches will be successful only in the recipient with
adequate postengraftment immune reconstitution, es-
pecially for the CMV-speciﬁc T cells. Vaccine-based
approaches for the immunosuppressed host are still
hindered by the major obstacle of producing an effec-
tive vaccine based on products other than live virus.
Even if such a vaccine were available, the best ap-
proach for its application remains to be deﬁned.
Should seropositive donors be boosted, or should se-
ronegative donors be vaccinated, with or without sub-
sequent stem cell recipient vaccination [103]? Al-
though immunotherapy seems to be the most
comprehensive approach in theory, practical clinical
application requires more intensive investigation.
CONCLUSIONS
Although many of the problematic issues of CMV
infection and disease in hematopoietic SCT recipients
remain active areas of investigation, signiﬁcant
progress has been made in reducing the clinical effects
of infection in recipients at low to average risk. How-
ever, the highly immunosuppressed recipient remains
at high risk for infection and subsequent late CMV
disease manifestations, as well as indirect effects of
CMV. Major advances in prevention of CMV infec-
tion occurred with the introduction of the antiviral
agent ganciclovir and the more widespread use of
sophisticated viral diagnostics. These advances, com-
bined with identiﬁcation of at-risk recipients, resulted
in effective application of the preemptive therapy ap-
proach to minimizing early viral infection. One sur-
prising ﬁnding is that the preemptive approach, al-
though highly effective in preventing CMV disease
(Table 3), has not eliminated the survival disadvantage
associated with CMV seropositivity in highly immu-
nosuppressed patients, such as recipients of T cell–
depleted grafts (Table 1). This may be due to indirect
effects of CMV not covered by preemptive therapy;
thus, prophylaxis using highly effective antivirals may
be warranted in these situations. However, drug tox-
icity remains a major impediment with currently avail-
able drugs. New anti-CMV drugs with improved
tolerability are needed. Meanwhile, prophylactic ap-
proaches with intensiﬁed supportive measures (eg,
ganciclovir or valganciclovir with the administration
of granulocyte colony-stimulating factor) may be
studied to examine whether preventing the effects of
neutropenia results in improved overall outcomes in
high-risk CMV-seropositive recipients. The increased
incidence of late CMV infection and disease is another
practical concern, because many recipients are no
longer under the care of the specialty oncology center
when reactivation occurs. The emerging issue of
drug-resistant viral mutations presents new challenges
for successful patient outcomes. Efforts to eliminate
the effects of CMV infection require the development
of improved antiviral agents and basic research on
more fundamental immunotherapy approaches.
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